A Conversation about Copaiba and CBD with Dr. Russell Osguthorpe
With the rising popularity of CBD (or Cannabidiol) as a health and wellness product, it has caught the interest of many, including top professionals in the medical field such as pediatric infectious disease specialist Dr. Russell Osguthorpe, also lovingly called “Dr. O”. Invited by his fellow practitioner and friend, Dr. David Hill, to the leading essential oil company doTERRA, they dove deep into a conversation comparing the benefits and potential downsides of CBD versus Copaiba. This discussion centered on four, critical aspects: Price, Purity, Potency, and Pathway.
Price, Potency, and Purity: Main Differentiators for CBD and Copaiba
CBD products have pervaded several markets, from beauty products like mascara to pet care items like doggy treats. However, Dr. Osguthorpe voiced out concerns about the price, potency, and purity issues affecting the CBD industry.
The Pricey Issue with CBD
In conditions where CBD could potentially improve a user’s well-being, the significantly high required doses create a big problem: the price. The cost for such amounts could be exorbitant and mostly unaffordable for an average consumer.
The Uncontrolled Purity of CBD
Next on the list is purity. Both doTERRA and Dr. Osguthorpe believe in the importance of consistent product purity. However, the lax regulation of the hemp industry, where CBD originates, raises concerns. CBD products lack standardized purity checks resulting in alarmingly variable CBD content between products. This issue may be driven by the discord between federal and state laws surrounding CBD.
Understanding the Endocannabinoid System (ECS)
This system plays a crucial role in balancing numerous functions within our bodies like eating, sleeping, forgetting, and relaxing. Our bodies naturally produce chemicals called endocannabinoids, which change the receptor tone of the ECS. Now, chemicals from plant sources which interact with ECS receptors are called phytocannabinoids. CBD, and a substance found in Copaiba called Beta-Caryophyllene, are examples of these.
How Beta-Caryophyllene and CBD Engage with ECS
The difference between CBD and Beta-Caryophyllene lies in how they integrate with the ECS receptors. Beta-Caryophyllene binds directly, while CBD binds indirectly. The method of binding introduces variations in how they potentially modulate ECS activities. That’s not to say that CBD lacks value, just that it operates under a different mechanism compared to Beta-Caryophyllene.
Copaiba Essential Oil vs. CBD: Potency and Diversity
When looking at Copaiba Essential Oil and CBD, their nature and effects dramatically differ. Far from being comparative products, the substantial amounts of Beta-Caryophyllene found in Copaiba may give users a more effective dosage with high potency.
New Discoveries about Copaiba
The purified product derived from Copaiba has shown a markedly high potency due to high amounts of Beta-Caryophyllene, which can directly bind to ECS receptors. This direct binding causes cellular mechanisms to change DNA proteins, enzymes, and cellular activities. It’s an exciting area of research that may potentially affect health outcomes substantially.
Copaiba: The Essential Oil with Diverse Benefits
Unlike CBD, Copaiba essential oil is rich in chemical diversity, which means that its benefits could venture beyond the ECS. It also contains other components, aside from Beta-Caryophyllene, which potentially offers effects beyond the ECS system.
Conclusion: The Future of Copaiba in the Marketplace
From an overall perspective, Copaiba seems to provide a more potent, pure, and affordable selection compared to CBD. This value is even more pronounced considering the small dosage required to gain its benefits. Coping with the four “Ps” – Potency, Price, Purity, and Pathway – it’s safe to say that with continuous research and technological advancements, Copaiba will carve its own niche in the marketplace.
